uploads///HAC

How Is Merck’s Hospital Acute Care Segment Positioned?

By

May. 30 2018, Updated 8:00 a.m. ET

Bridion

Merck & Company’s (MRK) Bridion generated revenue of $204 million in Q1 2018 compared to $148 million in Q1 2017, which reflected a ~38% rise YoY (year-over-year) and a 2% fall sequentially.

In Q1 2018, in US and international markets, Bridion reported revenues of $80 million and $124 million, respectively, compared to $45 million and $102 million, respectively, in Q1 2017, rises of ~76% and ~21% YoY, respectively.

Global demand for Bridion primarily pushed the drug’s revenue to rise in Q1 2018. Bridion is used in the reversal of neuromuscular blockades due to the introduction of rocuronium bromide and vecuronium bromide in patients going through surgical procedures.

Article continues below advertisement

Noxafil

Merck’s antifungal agent, Noxafil, generated revenue of $176 million in Q1 2018 compared to $141 million in Q1 2017, reflecting a ~25% rise YoY and a 2% fall sequentially.

In Q1 2018, in US and international markets, Noxafil generated revenues of $81 million and $94 million, respectively, compared to $65 million and $76 million, respectively, in Q1 2017, reflecting rises of ~25% and 24% YoY, respectively.

In the marketplace, Noxafil’s peers include Johnson & Johnson’s (JNJ) Nizoral and Pfizer’s (PFE) Vfend.

Invanz

In Q1 2018, Merck’s antibacterial agent, Invanz, reported revenue of $151 million compared to $136 million in Q1 2017, an ~11% rise YoY and a 4% fall sequentially.

In Q1 2018, in US and international markets, Invanz reported revenues of $91 million and $60 million, respectively, compared to $82 million and $54 million, respectively, in Q1 2017, rises of ~10% and ~11%, respectively, YoY.

Article continues below advertisement

Cancidas

In Q1 2018, Merck’s antifungal agent, Cancidas, reported revenue of $91 million compared to $121 million in Q1 2017, a ~25% fall YoY and a 4% fall sequentially.

Cancidas generated revenues of $3 million and $88 million, respectively, from sales in US and international markets in Q1 2018. Cancidas’s peers in the market include Pfizer’s (PFE) Eraxis and Astellas Pharma’s (ALPMY) Mycamine.

Cubicin and Primaxin

Cubicin reported revenue of $98 million in Q1 2018 compared to $96 million in Q1 2017, rises of ~2% YoY and 7% sequentially.

In Q1 2018, in US and international markets, Cubicin generated revenues of $47 million and $51 million, respectively, compared to $54 million and $41 million, respectively, in Q1 2017, falls of ~14% and ~23%, respectively, YoY.

Cubicin is used to treat individuals with methicillin-resistant Staphylococcus aureus infection. Cubin’s peers in the market include Pfizer’s (PFE) Zyvox.

In Q1 2018, Primaxin reported revenue of $72 million compared to $62 million in Q1 2017, a ~16% rise YoY and a ~3% fall sequentially.

Advertisement

More From Market Realist